| Name | Title | Contact Details |
|---|
Pharmaceutical Resource, Corp. is a Hatboro, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
As a company, we believe in digital health for everyone everywhere. We have created a new category of therapeutic product – the digital health feedback system – to allow people of all ages and cultures to power their own health, taking better care of themselves and each other. We see two trends: First, there are more people with mobile phones than there are with access to clean, running water. Second, chronic, often lifestyle-related diseases like diabetes are the world’s biggest healthcare problem, and our health systems can’t cope because they are optimized to treat the acute conditions prevalent decades ago. Our vision is to integrate medicines that treat chronic conditions with mobile technology – via our ingestible sensor – to make healthcare more accessible, manageable and innovative. We believe that by providing the right technology to individuals who deliver and receive healthcare, we can build a more effective healthcare system with new care paradigms focused on daily care and new information-based business models.
Higi began with a simple idea: being healthy should be simple, fun and rewarding. By making the process convenient and automated, we want to provide the most frictionless method for you to play an active role in your personal health and wellness. We are firm believers that understanding and tracking your data is the key first step to achieving your wellness goals. From your basic vitals to physical activity and nutrition, we are building solutions to help you do just that.
Morse Laboratories is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.